Source: Eur Respir J 2016; 47: 997-1000



Rating:

Share or cite this content

Citations should be made in the following way:
Cordier Jean-François, Cottin Vincent, Lazor Romain, Stoppa-Lyonnet Dominique. Monoallelic germline ATM mutation and organising pneumonia induced by radiation therapy to the breast. Eur Respir J 2016; 47: 997-1000

Member's Comments

No comment yet.

Related content which might interest you: p53 gene mutations in lung cancer in Korean Source: Eur Respir J 2005; 26: Suppl. 49, 327s Year: 2005 Germ-line exon 21 EGFR mutations, V843I and P848L, in nonsmall cell lung cancer patients Source: Eur Respir Rev 2014; 23: 390-392 Year: 2014 Mutation of TP53 and KRAS, and loss of p16ink4a and p14arf expression in lung cancers in relation to tobacco smoke Source: Eur Respir J 2005; 26: Suppl. 49, 93s Year: 2005 The analysis of CHEK2 gene mutation in small cell lung cancer Source: Virtual Congress 2021 – Novel insights into the pathogenesis of chronic lung diseases Year: 2021 The correlation between p53 gene mutation and the expression of tumor drug resistance genes in lung cancer and its clinical significance Source: Annual Congress 2005 - Prognostic factors in lung cancer Year: 2005 The development of mutant P53 characterized by lung cancers contributes to their primary and acquired multi-drug resistance to chemotherapy Source: Eur Respir J 2005; 26: Suppl. 49, 457s Year: 2005 Loss of heterozygosity off the P16, P53 and APC gene in oral cavity exfoliate cytologic material among lung cancer patients Source: Eur Respir J 2005; 26: Suppl. 49, 457s Year: 2005 The role of P53 tumor suppressor gene mutations in early diagnosis of lung cancer among patients with solitary pulmonary nodule Source: Annual Congress 2009 - Pathogenesis of lung cancer Year: 2009 Detection of k-ras mutations in cytologic specimen of lung cancer patients as predictive factor of targeted therapy Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 Arg72Pro P53 gene polymorphism is associated with P53 mutations in non-small cell lung cancer (NSCLC) patients Source: Eur Respir J 2004; 24: Suppl. 48, 78s Year: 2004 Homozygous deletion of PTEN and poor outcomes in EGFR mutant NSCLC patients with gefitinib therapy Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Dynamic monitoring of EGFR mutations in circulating tumor DNA for early detection of drug resistance in NSCLC patients on EGFR-TKI therapy Source: International Congress 2019 – Diagnostic procedures and biology of lung cancer Year: 2019 Polymorphisms A1026G and G369C of CDKN1A/p21 and p53 genes in lung cancer Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics Year: 2011 Survival prognosis and target therapy best response in adenocarcinoma lung cancer pts with mutation EGFR gene Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 Intercalating multimodal treatment strategy in a patient with advanced pulmonary adenocarcinoma harbouring the uncommon complex EGFR mutation L833V/H835L Source: International Congress 2018 – Lung cancer Grand Round Year: 2018 Combined effect of p53 and XRCC1 gene polymorphisms on age-associated lung cancer risk Source: Annual Congress 2008 - Discovery of novel targets in lung disease by means of functional genomics Year: 2008 Evaluation of EGFR mutations and ERCC2 polymorphisms in treatment of non-small cell lung cancer Source: Annual Congress 2005 - Chemotherapy and palliative care Year: 2005 KRAS & TP53 mutations cause malignant mesothelioma Source: ERS Lung Science Conference 2017 Year: 2017 NKX2-1 impacts prognosis in early stage NSCLC not harboring TP53 mutations Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016